Healthy Way: Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

Tuesday, December 9, 2014

Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

/ no comments Eli Lilly and Company; Incyte Corporation

Source:Arthritis drug baricitinib meets primary endpoint in Phase 3 RA-BEACON study

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)